Research programme: HIV vaccines - Sanofi
Latest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation; Partners AIDS Research Center
- Developer Partners AIDS Research Center; Sanofi
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 04 May 2006 No development reported - Preclinical for HIV-1 infections in USA (unspecified route)
- 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation
- 05 Dec 2002 This programme is still in active development